A medical professional has shed light on the phenomenon dubbed ‘Ozempic penis’ following findings that suggest the average penis size has increased.
Recent reports indicated that from 2022 to 2024, the average British penis size rose by 0.46 inches, increasing from 5.17 inches to 5.63 inches.
This statistic coincides with discussions about ‘Ozempic penis’, where many online have oddly claimed that the drug can ‘enhance’ the size of the male genitalia.
Ozempic is an injectable medication primarily prescribed to individuals with type 2 diabetes to assist with blood sugar regulation. It has gained traction in recent years among those looking to shed pounds.
Nonetheless, it has not received approval for weight loss purposes, unlike some other medications such as Mounjaro and Wegovy.
While some have proposed that Ozempic might increase penis size, the true explanation lies in weight loss, which can create the illusion of a larger penis.
Dr. Jen Caudle, known as ‘America’s family doctor’, clarified on her YouTube channel: “I am not aware of any data that these medications cause an increase in penis size. That’s not something they do. However, I think as men are losing weight, their penis is appearing larger.
“One way to help your penis look larger is losing weight. Why and how? It’s because the fat pad around your scrotal area, as that shrinks, your penis often looks larger. As men are losing weight, the penis is looking larger.”
This viewpoint is echoed by other medical professionals, such as Dr. Richard Viney, who shared with Diabetes.co.uk: “Men’s penises shorten as they get older (due to) increasing body fat and increasing prostate size drawing the penis back into the body.
“It is theoretically possible new drugs like Ozempic and Wegovy, which are used to treat diabetes and obesity respectively and can cause people to lose weight, could also be a factor. As men lose weight, their penises appear larger.”
In a statement, Novo Nordisk, the producer of Ozempic, emphasized: “Patient safety is of the utmost importance to Novo Nordisk, and we recommend patients take these medications for their approved indications and under the supervision of a healthcare professional. We continuously collect safety data on our marketed GLP-1 receptor agonists medicines and work closely with the authorities to ensure patient safety. As part of this work, we continue to monitor reports of adverse drug reactions through routine pharmacovigilance.
“We recommend that any patient experiencing side effects while taking GLP-1 RA medicines, including Wegovy®▼and Ozempic® (semaglutide injection), report them to their healthcare provider and via the MHRA Yellow Card scheme: https://yellowcard.mhra.gov.uk/.”